275 related articles for article (PubMed ID: 33785492)
21. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
[TBL] [Abstract][Full Text] [Related]
22. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
23. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
24. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis.
Robella M; Vaira M; De Simone M
World J Surg Oncol; 2016 Apr; 14():128. PubMed ID: 27125996
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A
Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
[TBL] [Abstract][Full Text] [Related]
26. A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers.
Dumont F; Passot C; Raoul JL; Kepenekian V; Lelièvre B; Boisdron-Celle M; Hiret S; Senellart H; Pein F; Blanc-Lapierre A; Raimbourg J; Thibaudeau E; Glehen O;
Eur J Cancer; 2020 Nov; 140():37-44. PubMed ID: 33039812
[TBL] [Abstract][Full Text] [Related]
27. Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: A multicenter study.
Sgarbura O; Hübner M; Alyami M; Eveno C; Gagnière J; Pache B; Pocard M; Bakrin N; Quénet F
Eur J Surg Oncol; 2019 Dec; 45(12):2386-2391. PubMed ID: 31092362
[TBL] [Abstract][Full Text] [Related]
28. Pressurized IntraPeritoneal Aerosol Chemotherapy with one minute of electrostatic precipitation (ePIPAC) is feasible, but the histological tumor response in peritoneal metastasis is insufficient.
Graversen M; Detlefsen S; Ellebaek SB; Fristrup C; Pfeiffer P; Mortensen MB
Eur J Surg Oncol; 2020 Jan; 46(1):155-159. PubMed ID: 31493986
[TBL] [Abstract][Full Text] [Related]
29. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
30. Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis.
Di Giorgio A; Schena CA; El Halabieh MA; Abatini C; Vita E; Strippoli A; Inzani F; Rodolfino E; Romanò B; Pacelli F; Rotolo S
Surg Oncol; 2020 Sep; 34():270-275. PubMed ID: 32891341
[TBL] [Abstract][Full Text] [Related]
31. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
[TBL] [Abstract][Full Text] [Related]
32. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
Nagasaka T; Mishima H; Sawaki A; Shimokawa M; Inukai M; Shinozaki K; Tanioka H; Nasu J; Nishina T; Hazama S; Okajima M; Yamaguchi Y
BMJ Open; 2016 Jun; 6(6):e011454. PubMed ID: 27256093
[TBL] [Abstract][Full Text] [Related]
33. Pressurized Intraperitoneal Aerosol Chemotherapy, a Palliative Treatment Approach for Patients With Peritoneal Carcinomatosis: Description of Method and Systematic Review of Literature.
Winkler CS; Sandhu J; Pettke E; Merchea A; Fong Y; Kumara HMCS; Whelan RL
Dis Colon Rectum; 2020 Feb; 63(2):242-255. PubMed ID: 31914116
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
[TBL] [Abstract][Full Text] [Related]
35. Pressurized IntraPeritoneal Aerosol Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer - study protocol for a randomized control trial.
Somashekhar SP; Ashwin KR; Rauthan A; Rohit KC
Pleura Peritoneum; 2019 Mar; 4(1):20180111. PubMed ID: 31198851
[TBL] [Abstract][Full Text] [Related]
36. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
37. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
38. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.
Gibbs P; Gebski V; Van Buskirk M; Thurston K; Cade DN; Van Hazel GA;
BMC Cancer; 2014 Dec; 14():897. PubMed ID: 25487708
[TBL] [Abstract][Full Text] [Related]
39. PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases.
Kim G; Tan HL; Sundar R; Lieske B; Chee CE; Ho J; Shabbir A; Babak MV; Ang WH; Goh BC; Yong WP; Wang L; So JBY
Clin Cancer Res; 2021 Apr; 27(7):1875-1881. PubMed ID: 33148667
[TBL] [Abstract][Full Text] [Related]
40. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).
Huiskens J; van Gulik TM; van Lienden KP; Engelbrecht MR; Meijer GA; van Grieken NC; Schriek J; Keijser A; Mol L; Molenaar IQ; Verhoef C; de Jong KP; Dejong KH; Kazemier G; Ruers TM; de Wilt JH; van Tinteren H; Punt CJ
BMC Cancer; 2015 May; 15():365. PubMed ID: 25943574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
